No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
CDMO240816C10000
- 0.62
- 0.000.00%
15min DelayClose Jul 16 13:35 ET
0.00High0.00Low
0.00Open0.62Pre Close0 Volume9 Open Interest10.00Strike Price0.00Turnover90.04%IV13.58%PremiumAug 16, 2024Expiry Date0.00Intrinsic Value100Multiplier24DDays to Expiry0.62Extrinsic Value100Contract SizeAmericanOptions Type0.4374Delta0.1811Gamma15.08Leverage Ratio-0.0183Theta0.0023Rho6.60Eff Leverage0.0095Vega
Intraday
- 5D
- Daily
News
Craig-Hallum Maintains Avid Bioservices(CDMO.US) With Buy Rating
Craig-Hallum Reaffirms Their Buy Rating on Avid Bioservices (CDMO)
Avid Bioservices (NASDAQ:CDMO) Is Making Moderate Use Of Debt
KeyBanc Maintains Avid Bioservices(CDMO.US) With Buy Rating, Maintains Target Price $14
Why Avid Bioservices Stock Is Moving Higher Wednesday
Avid Bioservices Shares Rise on Upbeat FY25 Outlook
Comments
Investors' belief in Societal CDMO's lackluster revenue performance not improving may be causing its low P/S ratio. The company's inferior revenue outlook compared to the industry average contributes to this. A significant change in fortune is needed to justify a higher P/S.
1
The company's high debt and lack of profitability strain its balance sheet. Negative free cash flow adds risk, but its US$417.4m market cap could potentially allow capital raising to strengthen the balance sheet.
Investors' belief in Avid Bioservices' stagnant revenue performance and future growth lagging behind the industry has led to its low P/S. The underwhelming revenue outlook and shareholders' pessimism impact the P/S negatively.
Despite good revenue growth, the market expected more, as seen in the share price drop. This could hint at delayed revenue growth. The recent sell-off might be an investment chance considering the signs of a continued growth trend.
Read more